Aminosyn 3.5% M, Sulfite Free is in shortage. Learn why this IV amino acid solution is hard to find in 2026 and what patients can do about it.
If you or a loved one relies on parenteral nutrition (IV nutrition), you may have already discovered how difficult it can be to get Aminosyn 3.5% M, Sulfite Free in 2026. Hospitals, home infusion pharmacies, and patients across the country have been dealing with limited supply of this critical amino acid injection for years — and the situation hasn't fully resolved.
This article explains what Aminosyn 3.5% M, Sulfite Free is, why it's been so hard to find, and what steps you can take to make sure you or your loved one continues to receive the nutrition they need.
Aminosyn 3.5% M, Sulfite Free is a sterile intravenous (IV) solution that provides essential and nonessential amino acids — the building blocks of protein — along with maintenance electrolytes like sodium, potassium, magnesium, and phosphorus. It is part of a category of medications known as parenteral nutrition products.
This product is used when a patient cannot eat by mouth or absorb nutrition through their digestive tract. Common situations include:
The "3.5% M" designation means it contains 3.5% amino acids with maintenance ("M") electrolytes, and it is formulated without sulfites — important for patients with sulfite sensitivities. Because of its lower concentration, it can be administered through a peripheral vein (a regular IV line), unlike higher-concentration amino acid products that require a central venous catheter.
To learn more about this medication's full profile, see our guide: What Is Aminosyn 3.5% M, Sulfite Free? Uses, Dosage, and What You Need to Know.
There are several overlapping reasons why this medication has been in shortage, and understanding them can help you plan ahead.
The market for IV amino acid solutions is dominated by just a handful of companies — primarily Pfizer (through its Hospira division) and ICU Medical, along with Baxter, which makes competing products like Travasol and Clinisol. When one manufacturer experiences a production issue, there simply aren't enough alternative suppliers to pick up the slack.
Unlike common oral medications that have dozens of generic manufacturers, sterile injectable products require specialized manufacturing facilities that meet strict FDA standards. Building new capacity takes years and billions of dollars.
The amino acid injection market has been hit by multiple disruptions. In 2023, ICU Medical issued a voluntary nationwide recall of Aminosyn II 15% due to the presence of particulate matter. Recalls like this remove product from an already-tight supply chain and create ripple effects across all amino acid formulations — including the 3.5% M version.
Manufacturing sterile IV solutions is complex. Even minor quality issues can shut down production lines for weeks or months while problems are corrected and FDA inspections are completed.
Since late 2024, the entire IV fluid supply chain in the United States has been under stress. Natural disasters, including the impact of hurricanes on manufacturing plants in Puerto Rico and North Carolina, disrupted production of IV bags and solutions broadly. While Aminosyn is not an IV fluid in the traditional sense, it shares manufacturing infrastructure and supply chain components with saline, dextrose, and other IV products.
The American Society of Health-System Pharmacists (ASHP) currently lists amino acid products as being in active shortage, and the American Society for Parenteral and Enteral Nutrition (ASPEN) published specific shortage recommendations for amino acid products in 2025.
The number of patients requiring parenteral nutrition has been steadily increasing. An aging population, more complex surgeries, and a growing number of patients with conditions like short bowel syndrome have all increased demand for amino acid injection products. When supply is constrained and demand is rising, shortages become worse.
If you're struggling to find this medication, here are practical steps to take:
Medfinder helps patients locate medications that are in short supply. Instead of calling pharmacy after pharmacy, you can search for Aminosyn 3.5% M, Sulfite Free and find pharmacies that currently have it in stock.
Several other amino acid injection products may be substituted depending on your clinical situation. Products like Travasol, Clinisol, FreAmine III, and Aminosyn II (in different concentrations) are considered therapeutically equivalent on a gram-for-gram basis. Your healthcare team can determine the best alternative for your needs. Read more in our article: Alternatives to Aminosyn 3.5% M, Sulfite Free.
If you receive parenteral nutrition at home, your home infusion pharmacy is your best ally. These specialized pharmacies often have relationships with multiple distributors and may be able to source products that retail pharmacies cannot. Ask them about their current supply and any backup plans they have in place.
In some cases, compounding pharmacies that specialize in sterile preparations may be able to prepare amino acid solutions. The FDA has granted compounding flexibilities during shortage periods to help maintain patient access. Your doctor or pharmacist can advise whether this is an option for you.
The shortage of Aminosyn 3.5% M, Sulfite Free is frustrating, especially for patients who depend on IV nutrition to survive. But understanding why the shortage exists and knowing your options can help you stay ahead of supply disruptions.
Stay informed by checking the latest shortage updates, and use tools like Medfinder to locate available supply near you. If you're a healthcare provider looking for resources, visit our provider shortage guide.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
